cholestane-3,5,6-triol has been researched along with Prostatic Neoplasms in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chang, JY; Chen, L; Chen, YW; Chuu, CP; Fu, HH; Fukui, Y; Hiipakka, RA; Hung, Y; Huo, C; Jones, RB; Kao, YH; Kokontis, JM; Kuo, LK; Kuo, YY; Lin, CY; Lin, HP; Su, LC; Tsai, KK; Tseng, JC; Wang, YL; Yang, SD; Yeh, CC | 1 |
1 other study(ies) available for cholestane-3,5,6-triol and Prostatic Neoplasms
| Article | Year |
|---|---|
Cholestane-3β, 5α, 6β-triol suppresses proliferation, migration, and invasion of human prostate cancer cells.
Topics: Actins; Androgens; Animals; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cholestanols; Disease Models, Animal; Epithelial-Mesenchymal Transition; G1 Phase Cell Cycle Checkpoints; Gene Expression; Humans; Liver X Receptors; Male; Mice; Neoplasm Invasiveness; Orphan Nuclear Receptors; Phosphorylation; Prostatic Neoplasms; Proteome; Proto-Oncogene Proteins c-akt; S-Phase Kinase-Associated Proteins; Signal Transduction; Tubulin; Tumor Burden; Tumor Stem Cell Assay; Xenograft Model Antitumor Assays | 2013 |